目的:研究非何杰金氏淋巴瘤患者之特性及腫瘤基因表現與其淋巴結復發病灶對放射治療效果之關係，以提供臨床上評估放射治療效果之參考。材料與方法:16例化學治療後發生淋巴結復發的患者，經病理切片証實診斷後，其中10例患者之組織切片蠟塊仍可供應各種腫瘤基因產物之免疫組織化學染色。於是將各種染色結果與病患復發處淋巴結經照射後的效果，用單變數及多變數統計方法評估其相關性，並與病患基本資料一併比較之。結果:在單變異數分析方面，發現CD44表現與放射治療抵抗性有顯著相關性(p=0.011),多變異數分析結果則顯示CD44及比bcl-2過度表現亦具有上述相關性。結論:研究結果顯示CD44及bcl-2基因表現在預測非何杰氏淋巴瘤患者之放射治療效果上具有一定的角色，惟仍需更多病例及前瞻性研究做進一步證實。

　　　　　Purpose: To examine the relationship of patient characteristics, oncogenesexpression with one another and assess their correlation to nodal RT resistance innon-Hodgkin's lymphoma (NHL) patients.Materials and Methods: 16 NHL patients after chemotherapy with nodal relapse wereeligible in this study. Immunohistochemical stain with various monoclonal antibodieswas applied to stored fixed-paraffin-embeded nodal biopsy specimen from 10 availablepatients. Univariate and multivariate analysis of relationship between variableswere per-formed using Fishers exact test and logistic regression model, respectively.Results: We find that expression of CD44 is significant associated with nodal RTresistance in univariate analysis (p=0.011). Moreover, multivariate analysis of allvariables by a logistic regression model reveals the significant association of CD44and bcl-2 overexpression to nodal RT resistance (p=0.0112 and 0.0455, respectively).Conclusion: The results suggest an important role of CD44 and bcl-2 in a clinicalpredictive model of nodal RT responses in NHL patients.